Evaluation of Clinical Effectiveness of Platelet Rich Fibrin and Bone Graft in Management of Intrabony Defects: A Comparative Study. by Shruti, Beri
EVALUATION OF CLINICAL EFFECTIVENESS OF 
PLATELET RICH FIBRIN AND BONE GRAFT IN 
MANAGEMENT OF INTRABONY DEFECTS : 
A COMPARATIVE STUDY 
 
A Dissertation submitted in  
partial fulfillment of the requirements  
for the degree of 
 
 
MASTER OF DENTAL SURGERY 
 
 
 
BRANCH – II 
PERIODONTICS 
 
 
 
 
 
 
 
 
 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
Chennai – 600 032 
 
2010 - 2013 
 
 
CERTIFICATE 
 
This is to certify that Dr. SHRUTI BERI, Post Graduate student (2010-2013) 
in the Department of Periodontics, Tamil Nadu Government Dental College 
and Hospital, Chennai - 600 003, has done this dissertation titled 
"EVALUATION OF CLINICAL EFFECTIVENESS OF PLATELET 
RICH FIBRIN AND BONE GRAFT IN MANAGEMENT OF 
INTRABONY DEFECTS : A COMPARATIVE STUDY ”  under the direct 
guidance and supervision in partial fulfillment of the regulations laid down by 
the Tamil Nadu Dr. M.G.R. Medical University, Chennai - 600 032 for 
M.D.S., (Branch-II) Periodontics degree examination. 
 
  
 Dr. K. Malathi 
         Professor and Guide 
Dr. K. Malathi 
Professor & H.O.D. 
 
Department of Periodontics 
Tamil Nadu Government Dental College and Hospital 
Chennai - 600 003. 
 
 
 
 
 
Dr. K.S.G.A. NASSER 
PRINCIPAL 
Tamil Nadu Government Dental College and Hospital 
Chennai - 600 003 
  
 ACKNOWLEDGEMENT  
I gladly utilize this opportunity to express my deep sense of gratitude to my 
respected teacher and guide DR. K. MALATHI M.D.S., Professor and H.O.D., 
Department Of Periodontics, Tamil Nadu Government Dental College and Hospital, for 
her understanding nature, ever encouraging attitude and constant motivation throughout 
my PG course. She gave me the inspiration to begin and the courage to sustain my 
efforts, for which I am indebted to her. 
 I offer my sincerest gratitude to Dr. S.KALAIVANI M.D.S., Professor, and      
Dr. MAHEASHWARI RAJENDRAN M.D.S., Professor, Department of Periodontics, 
Tamil Nadu Government Dental College and Hospital, Chennai for their valuable 
support and continuous encouragement throughout the study. 
I am immensely indebted to Dr. K.S.G.A. NASSER, M.D.S., Principal, Tamil Nadu 
Government Dental College and Hospital, for being a helping hand in providing required 
facilities and infrastructure.  
I am extremely grateful to DR.A.MUTHUKUMARASAMY, M.D.S., Assistant 
Professor, Department Of Periodontics, Tamil Nadu Government Dental College and 
Hospital for guiding me in the intricacies of my research. Without his contributions and 
guidance, this study would not have been possible.  
I am grateful to Dr. M.JEEVA REKHA M.D.S., and Dr. P.KAVITHA, M.D.S., 
Assistant Professors, Department Of Periodontics, Tamil Nadu Government Dental 
College and Hospital, for their valuable suggestions and constant encouragement 
throughput  my study period. 
  
I extend my sincere thanks to Dr. JAYCHANDRAN, M.D.S., Professor and 
H.O.D., Department of Oral medicine and Radiology for extending his full support in 
carrying out the radiographic analysis.  
I would like to extend my gratitude to Dr. Shashi Kumar, ex- Post Graduate 
student, Department of Oral Medicine and radiology for sparing his time and helping me 
performing the radiographic analysis.  
I sincerely thank Dr. Venkatesh, Department of Statistics, SRMC, Porur, 
Chennai, for helping me with the statistical analysis and interpretation.  
I am thankful to all my colleagues, especially Dr. S. Kiruthika, Dr. K. Kirupa, my 
seniors and my juniors for their co-operation and help whenever I needed. 
I am thankful to all my patients for their consent, co-operation and participation 
in the study. 
I would like to extend my sincere and deep regards to my Parents and my family 
for their unconditional love, support and sacrifices; for their limitless faith in me and for 
their constant prayers that have guided me through my goals in life. Also, a special 
thanks to my husband Dr. Himanshu Arora, MBBS,DO,DNB who has been on my side in 
times good and bad and boosted my morale constantly. 
 Also, a special salutation to The Almighty Lord, whose continuous divine Grace 
in my life in times easy and tough, has bestowed me with immense courage and 
perseverance to fight all odds, and has made me what I am. 
 
 
ABSTRACT 
Background : Periodontal therapy aims to prevent periodontal tissue destruction 
while achieving regeneration of  lost and damaged tissues. Demineralized bone matrix 
(DMBM) is a xenograft with acceptable clinical responses in the field of periodontal 
regeneration. Platelet Rich Fibrin (PRF) is the latest advancement in fibrin technology 
and is a rich autologous source of various growth factors and leukocytes. PRF has a 
strong potential to influence the cellular mechanisms responsible for periodontal 
regeneration to be achieved. A combination of the two grafting modalities may prove 
to be an advantageous regenerative treatment option for management of intrabony 
defects. 
Aim: The aim of this study was to clinically and radiographically evaluate, the 
additional effectiveness of autologous PRF, when used in combination with bone graft 
(DMBM) as compared to bone graft (DMBM) alone, in the treatment of intrabony 
defects. 
Methods : A total of 18 intrabony defects in 15 systemically healthy patients were 
selected randomly for the purpose of the study. The defects were equally divided into 
two groups and treated with DMBM alone and in combination with PRF. Clinical 
parameters such as plaque index (PI), gingival bleeding index (GBI), probing pocket 
depth (PPD), and clinical attachment level (CAL) were recorded at baseline and at 6 
months post-operatively. In both the groups, radiographic analysis was performed at 
baseline, and at 3 months and 6 months post operatively. 
Results :. Significant reduction in post- operative mean pocket depth and gain in 
attachment level was observed in PRF-DMBM and DMBM groups as compared to 
baseline. Also, greater attachment gain was observed in PRF-DMBM group post-
operatively. Radiographically, at the end of 6 months, reduction in defect depth was 
significantly greater in PRF-DMBM group than DMBM group (p=0.007). Greater gain 
in percentage of bone fill was observed for PRF-DMBM group than for DMBM group 
at 6 months. Percentage of original defect resolution was statistically greater in PRF-
DMBM group (40.23 ±29.41 %) as compared to DMBM alone (12.43±14.14 %) at 3 
months. 
Conclusion : Autologous PRF when added to DMBM demonstrated additional 
effectiveness and ability to augment the effects of bone graft material, clinically and 
radiographically in management of periodontal intrabony defects.  
Keywords : Demineralized bone matrix, Intrabony defect, Periodontal Regeneration, 
Platelet Rich Fibrin. 
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INTRODUCTION 
 The goal of periodontal therapy includes arrest of periodontal disease 
progression and the regeneration of structures lost due to pre-existing disease process. 
Conventional surgical techniques offer only limited potential towards recovering the 
lost periodontal structures. 
Successful periodontal reconstruction comprises of regeneration of multiple 
tissues of the periodontium. It is a complex biological process in itself which is 
intricately regulated between cells, locally acting growth factors and the extracellular 
matrix components. The key to periodontal regeneration is to stimulate the progenitor 
cells to re-occupy the defect 
44
.  
Earlier attempts to achieve regeneration included denudation of interdental 
bone to treat intrabony defects and use of autografts to fill the surgical site. Also, 
favourable results have been gained in treatment of such defects using a combination 
of graft material and collagen membranes.
84
 
However, recently, the attention has shifted to the use of growth factors which 
are the biologic mediators that can regulate the proliferation, chemotaxis and 
differentiation of the locally derived progenitor cells in the defect site.
17
 
Among the rich sources of autologous growth factors the various generations 
of platelet concentrates are currently in use. Platelet Rich Plasma, first generation 
concentrate, has been used alone and in combination with grafting materials and 
barrier membranes in treatment of periodontal and surgical defects.
3,13,35
 However, the 
effects of Platelet rich plasma on bone regeneration have been limited. 
___________________________________________________________________Introduction 
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The second and latest generation of platelet concentrates is Platelet Rich 
Fibrin. It is a promising, completely autologous leukocyte and platelet concentrate 
which is being successfully used in various fields of dentistry and medicine. PRF has 
shown successful results when used as a sole agent in the treatment of periodontal 
intrabony defects 
100
. However, limited research is available for PRF as a combination 
therapy with bone graft materials.
62, 78
 
It remains to be evaluated how well a combination of commercially available 
grafts and autologous growth factors can alter or enhance the potential for 
regeneration. 
Hence, the present study has been undertaken to evaluate and compare clinical 
and radiographic effectiveness of combination of platelet rich fibrin with bone graft in 
relation to bone graft alone. 
 
  
   
____________________________________________________________ Aim  and  Objectives 
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AIM 
The aim of the present study is to investigate the additional effectiveness of 
autologous PRF with bone graft (DMBM) in the treatment of three wall intrabony 
osseous defects in comparison with bone grafts alone (DMBM) . 
OBJECTIVES 
The objectives of the study included : 
1. To clinically evaluate and compare the use of PRF and bone graft (DMBM) in the 
management of intrabony osseous defects. 
2. To radiographically compare and assess the regeneration of lost alveolar bone by 
PRF and bone graft (DMBM) in the management of intrabony osseous defects. 
 
  4 
REVIEW OF LITERATURE 
 
1. REGENERATION OF PERIODONTAL TISSUES 
 
Periodontitis is an inflammatory disease characterized by destruction of 
alveolar bone, root cementum, periodontal ligament and gingiva as a response to 
insults elicited by microbial accumulations on tooth surfaces.
59
  These responses can 
result in variety of intraosseous defects of various architectures. 
Periodontal regeneration refers to complete restoration of functional 
supporting tissues, including alveolar bone, cementum and periodontal ligament. It is 
defined as the reproduction or reconstruction of lost or injured part with form and 
function of lost structures restored.
2
 
Melcher et al
70
 in 1976 proposed the type specific repopulation theory, which 
was further established by Gotlow et al
44
 in 1986. The theory states that, different 
periodontal connective tissues compete for the root surface during healing each 
resulting in a selected cell population occupying the periodontal wound and resulting 
in a specific type of repair or regeneration.  
Trombelli et al
104
 in 2002, in their systematic review reported various grafting 
modalities and bone substitutes that have been in use over the years for regenerative 
purposes. They compared results of open flap debridement alone and in combination 
with graft materials and concluded implantation of graft materials provided 
favourable results such as gain in clinical attachment levels, reduction in pocket 
probing depths and gain in defect fills. 
Needleman
74
 in 2002 and Giannobile & Somerman
42
 in 2003, in their 
respective systematic reviews on application of guided tissue regeneration and enamel 
____________________________________________________________ Review of Literature  
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matrix derivatives reported significant increase in clinical attachment levels (CAL), 
however the magnitude of the observed additional benefits were modest. 
Although, periodontal regeneration is a possible objective of several 
periodontal therapeutic modalities, outcomes of such modalities are not always 
predictable. Complete regeneration may be an unrealistic goal for many situations due 
in part to the complexity of the biological events and cells underlying successful 
periodontal regeneration.
84 
Wang et al
106
 in 2006 concluded that various factors which determine the 
predictability of bone regeneration include primary wound closure, blood supply, 
defect architecture, space maintenance and wound stability. All these factors play a 
significant role in deciding the amount and extent of achievable regeneration via 
various grafting modalities. 
2. BONE GRAFTS  
Regeneration of lost bone and periodontal attachment apparatus can improve 
the health of supporting periodontal tissues. Bone replacement grafts have been used 
to facilitate and promote this periodontal regeneration. 
As early as 1923 Hegedus
49
 reported rebuilding of the alveolar process by 
bone transplantation. In 1971, Shaffer
93
 used plaster of paris as one of the first 
synthetic implant material used in periodontics. Since then, bone replacement graft 
materials have fascinated various surgeons for their application and successful 
outcomes in treatment of bony defects.  
To achieve successful regeneration any substitute should be biologically 
compatible, non-toxic and provide scaffolding for angiogenesis and new bone 
outgrowth. A graft material must possess either osteogenic, osteoinductive or 
____________________________________________________________ Review of Literature  
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osteoconductive activity. Broadly, bone grafts are classified as autografts, allografts, 
xenografts and alloplasts. 
Froum et al
37
 in 1976 clinically evaluated and compared responses of human 
periodontal defects following open debridement with and without the subsequent 
implantation of an osseous coagulum-bone blend graft and reported greater levels of 
osseous regeneration with the autogenous graft procedures than following open 
debridement alone. 
Petite et al
76
 in 2000, concluded that autogenous bone grafts are the preferred 
choice for any regenerative procedure, however patient morbidity, limited supply of 
suitable bone, painful procurement, risk of infection, nerve damage and haemorrhage 
remain the factors of concern. 
Reynolds et al 
84
 in 2003 in their systematic review on comparing the variety 
of bone replacement grafts concluded  that bone grafts increase bone level, reduce 
crestal bone loss, increase clinical attachment level and reduce probing depth 
compared to open flap debridement. Also, no differences in clinical outcome 
measures were observed between particulate bone allografts, and bovine derived 
xenografts.  
2.1 Demineralized bone matrix (DBM) 
It was first observed by Urist 
105 
in 1965 to induce heterotopic bone. The 
active components of DBM are a series of glycoproteins,  transforming growth factor 
family (TGF-β) and bone morphogenic proteins (BMP). It demonstrates the property 
of osteoinduction and regulates morphogenic events involved in the development of 
tissue and organs.  It stimulates the proliferation of undifferentiated mesenchymal 
cells through stimuli provided by demineralised bone matrix.  
____________________________________________________________ Review of Literature  
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DBM has been used for several decades in human surgery in treatment of non-
union, facial deformities, osteomyelitis and large defects resulting from tumor 
removal. Bingel
8
 in 1999, used DBM with good results for healing of fractures and 
bone defects in animal models. 
Geesink et al
41
 in 1999evaluated osteogenic activity of to demineralized bone 
matrix (graftonTM) with controls in a human fibular defect. During the first 
postoperative year in the untreated group, no bony changes were observed while, in 
the Grafton DBM bone group, formation of new bone was visible from six weeks 
onwards.  
Lee
60
 in 2005, compared the efficacy of different commercially available 
demineralised bone matrix substances in animal models. The results of this study 
suggest that DBM implants may enhance cementum regeneration in this defect model.  
Wang
107
 in 2007 compared the commercially available demineralized bone 
matrices for spinal fusion. There was no statistically significant difference between 
the rate of fusion after implantation of OsteofilTM and GraftonTM. 
 Till date, the main delay in developing clinical products has been the need to 
find a suitable carrier to deliver the BMP to the site at which its action is required. 
2.2 Bovine Derived Demineralized  bone matrix  
In recent times, a new demineralized bone matrix (DMBM; osseograftTM) has 
been introduced.  It is a sterile bioresorbable xenograft composed of type I collagen. It 
is prepared from bovine cortical bone samples, which result in nonimmunogenic 
flowable particles of approximately 250µm that are completely replaced by host bone 
in 4-24 weeks.
10 
____________________________________________________________ Review of Literature  
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Its xenogenic origin makes it an osteotropic matrix that provides improvement 
of bone formation by its chemical or structural characteristics in presence of 
osteogenic precursor cells. Xenogenic bone substitutes are osteoconductive in nature. 
They provide a scaffold to allow ingrowth and deposition of bone by osteoblasts from 
the margins of the defect on bone graft material. 
The advantages of DMBM include being a totally resorbable space maintainer. 
It is deemed to be osteoconductive as well as oseoinductive in nature. It is cost 
effective and easy to handle and place. 
A xenogenic graft is obtained from a donor of different species. Thus a 
limiting factor previously associated with the use of such materials was the potential 
of cross species antigenicity. However, the histological evaluation by Sogal, Tofe
96
 in  
1999 confirmed the tolerance and good tissue acceptance of xenografts revealing no 
inflammation and almost completely free of risk of disease transmission . 
Seyedin and Thomas
92
 in 1985 isolated two naturally occurring peptides 
cartilage-inducing factors (CIF-A and CIF-B) from bovine demineralized bone by 
chemical treatment,  that induce chondrogenesis. 
Blumenthal et al
10
 in 1986 studied the healing response of collagen gel in four 
dogs , evaluated  it over 24 weeks and observed that collagen gel encouraged 
ingrowth of regenerative tissue-fibroblasts in the early stages of wound healing. 
Choi
18
 in 1993 reported that Type I collagen fulfils some of the criteria for 
bone formation. It stimulates osteoblast proliferation and differentiation of bone 
marrow cells. Since it is chemotactic for osteoblasts, fibroblasts and endothelial cells, 
it has been used for treatment of empty sockets, periodontal fenestrations and bone 
defects. 
____________________________________________________________ Review of Literature  
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Garcia RR, Barbosa JR
39
 in 2000 performed a histologic study of a bovine 
demineralized bone matrix on bone repair process in rabbits calvaria. Nine rabbits 
were used and two surgical defects were created on each calvaria, one was just filled 
with the animal blood and the other was filled with demineralized bone matrix. The 
animals were sacrificed at postoperative period of 3, 7, and 15 weeks. Specimens on 
light microscopy analysis revealed that bone repair was improved on cavities filled 
with bovine demineralized bone matrix. 
Gupta, Pandit et al
45
 in 2007, performed clinical and radiographic evaluation 
of an osseous xenograft for the treatment of intrabony defects. They assessed the 
effectiveness of DMBM at 40 sites on 30 patients at 3 months and 6 months post-
operatively. In comparison to open flap debridement, significant improvements were 
observed in probing depths, clinical attachment levels and bone fill. 
Kumaran et al
57
 in 2010, compared the osteoblastic responses of 
commercially available demineralised bone matrices in an invitro study. They 
compared graftonTM and osseograftTM in bone marrow stem cell cultures (BMSCs) and 
observed an increased proliferative activity of osteoblasts  in BMSCs in both cases for 
initial 5-10 days of culture. They also observed increased alkaline phosphatase 
activity when compared to control groups. 
 
____________________________________________________________ Review of Literature  
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3. PLATELETS & PLATELET CONCENTRATES 
Platelets are un-nucleated fragments of bone marrow megakaryocytes which 
circulate in blood for 8-10 days.
28
 Historically, platelets are thought to contribute to 
the hemostatic process, where they adhere together to form a platelet plug in a severed 
vessel and actively extrude several initiators of the coagulation cascade. 
Ross et al
86
 in 1974 introduced the regenerative potential of platelets by 
discussing their role in wound healing. The alpha granules of platelets contain various 
mitogenic factors such as platelet derived growth factor, vascular endothelial growth 
factor and transforming growth factor –β.  This storage pool of growth factors 
proteins is vital to initial wound healing.  Upon connective tissue contact, as occurs in 
injury or surgery, the cell membrane of the platelet is "activated" to release these 
alpha granules. 
 Active proteins are thus secreted which bind to transmembrane receptors of 
the target cells to activate intracellular signalling proteins. This results in expression 
of a gene sequence that directs cellular proliferation, collagen synthesis and osteoid 
production.
68
 
3.1 Platelet concentrates 
Application of fibrin adhesives in surgical management of haemostasis is well 
documented since early 1900s. These correspond to a natural biologic mechanism of 
fibrin polymerization, amplified in an artificial way. Thus yesteryear fibrin adhesives 
paved the way for the present day platelet concentrates.  
Concentrating blood components via centrifugation provides with an 
opportunity to amplify the rich and advantageous components of patients own blood.  
Platelet rich plasma and platelet rich fibrin are two such emerging platelet 
____________________________________________________________ Review of Literature  
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concentrates. These are basically fibrin matrices enmeshed with morphogenic proteins 
(growth factors) and leukocytes.  
Fabbro et al
36
  summarised the ideal role of platelet concentrates as: 
1. Augmentation of tissue healing : By increased proliferation of connective 
tissue progenitors that stimulate fibroblast and osteoblast activity  and enhance 
osteogenesis.
67
 
2. Anti-microbial activity :Against bacterial species involved in oral 
infections.
100 
 
3. Modification of host defence mechanism : By delivery of signalling peptides 
that attract macrophage cells.
65
 
4. Modification of immune reaction: By releasing leukocytes that synthesize 
interleukins.
26
 
3.2    Platelet Rich Plasma  
 The first generation of platelet concentrate, which consists of a limited 
volume of plasma enriched with platelets obtained from the patient, was called 
platelet rich plasma (PRP). If a normal human blood clot contains 5% platelets, 
according to Sunitha et al 
99
, a PRP blood clot contains 95% platelets. 
 PRP is known to contain growth factors such as PDGF and TGF – β, that may 
influence the regenerative process. Also in-vitro studies by Creeper et al
24
 have 
reported proliferation of PDL and osteblastic cells under the influence of PRP.
 
Although PRP contains growth factors, their release in wound site tends to be 
rapid and for a short duration of time. Also, complex production protocol involving 
use of bovine thrombin and other biochemical agents has limited the benefits of 
platelet rich plasma.
88
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Lekovic et al
61
 in 2002, for the management of intrabony defects, compared 
platelet rich plasma, bovine porous bone mineral and guided tissue regeneration with 
a combination of platelet rich plasma and bovine porous bone mineral for the 
management of intrabony defects. They reported effective results in both groups. 
However, GTR appeared to add no clinical benefit to PRP and BPBM. 
Hanna R et al
47
 in 2004 compared the clinical outcomes obtained by the 
combination of PRP and a bovine derived xenograft (BDX) to those obtained from the 
use of the bone replacement graft alone, in a 9 months clinical trial. The addition of a 
high concentration of autologous platelets to a bovine derived xenograft to treat 
intrabony defects significantly improved their clinical periodontal response. 
Dori et al
33
 in 2007 studied the effect of platelet rich plasma on the healing 
of intrabony defects treated with a natural bone mineral and collagen membrane. The 
result concluded equally significant clinical outcomes in both the groups. However, 
the use of PRP failed to improve the results obtained with combination of PRP and 
natural bone mineral. 
Dori et al
34 
in 2007 evaluated the effect of platelet rich plasma on the healing 
of intrabony defects treated with an anorganic bovine bone mineral and expanded 
polytretrafluoroethylene membranes. Optimal clinical results were obtained with 
ABBM+GTR with or without the addition of PRP. 
Piemontese
77
 in 2008 treated periodontal intrabony defects with 
demineralized Freeze-Dried Bone Allograft in combination with Platelet-Rich 
Plasma. Treatment with a combination therapy led to a significantly greater clinical 
improvement in intrabony periodontal defects compared to DFDBA with saline. 
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However, no statistically significant differences were observed in the hard tissue 
response between the two treatment groups, which confirmed that PRP had no effect 
on hard tissue fill or gain in new hard tissue formation. 
Parimala et al
75
 in 2010 performed a comparative evaluation of bovine porous 
bone mineral with and without platelet rich plasma. Significant results were observed 
with both treatment modalities in probing depth reduction, gain in clinical attachment 
level and amount of defect fill. Although the mean difference between two groups 
was statistically non-significant, more favourable results were observed with 
combination therapy. 
The potential benefits of PRP have been variable in literature. Although some 
authors reported significant improvements in tissue healing and bone formation using 
PRP
67, 6, 86
, others failed to observe improvement.
83,46
 Benefits of treating intrabony 
periodontal defects with PRP combined with bone mineral were reported. However, 
the final consensus of PRP on bone grafts remains questionable. 
Thus, the technical and regenerative limitations of platelet rich plasma led to 
the discovery of a better, completely autologous fibrin matrix called Platelet Rich 
Fibrin.  
3.3  Platelet Rich Fibrin 
A second generation platelet concentrate, developed in France in 2001 by 
Choukroun.et al 
19
, is an autologous growth factor reservoir which attempts to 
accumulate platelets and cytokines in a physiologic fibrin clot. 
PRF clot concentrates 97 % of platelets and >50 % of leukocytes in a specific 
three dimensional distribution. It consists of intimate assembly of cytokines, glycanic 
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chains and structural glycoproteins enmeshed within a slowly polymerized fibrin 
network.
28 
3.3.1 Significance of PRF : 
1. Role of fibrin matrix   
A soluble fibrillary molecule, fibrin is an activated form of plasmatic 
molecule fibrinogen that is massively present both in plasma and  in the platelet alpha 
granules which is transformed into an insoluble fibrin by thrombin. The polymerized 
fibrin gel constitutes the first cicatricial matrix of the injured site.
27, 28
 
The three dimensional structure of the matrix resembles that of physiologic 
fibrin.
31
 The enmeshed cytokines influence the extracellular matrix which allows 
migration, division and phenotypic change of endothelial cells, thus leading to 
angiogenesis.
50
 
2. Role of platelets and growth factors 
Periodontal regeneration is a multi-factorial process and requires an 
orchestrated sequence of biological events including cell adhesion, migration, 
multiplication and differentiation.
43
 
The scientific rationale behind the use of platelet concentrates lies in the fact 
that the platelet α granules are a reservoir of many growth factors (GFs) that are 
known to play a crucial role in hard and soft tissue repair mechanism
3,13
. Platelet 
growth factors exhibit chemotactic and mitogenic properties that promote and 
modulate cellular functions involved in tissue healing, cell proliferation and 
regeneration .
5
 
The growth factors released by α granules encompass a group of cytokine 
polypeptides with relatively low molecular weight ranging from 6-45kDa. PRF 
growth factors include Platelet derived growth factors (PDGFs), Transforming growth 
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factor –β (TGF-β), Vascular endothelial growth factor (VEGF), Epidermal growth 
factor (EGF) and  Insulin-like growth factor -1(IGF-1).
28 
a. PDGF : It was first described by Ross et al 86 in 1974 as a factor which 
accelerate proliferation of monkey arterial smooth muscle cell in cell culture. 
The types of PDGF include PDGF AA, BB, AB, CC, DD the classic dimmers 
being AA, AB and BB.  
  PDGF AB and BB are released from platelets at injury site whereas 
AA   isoform is secreted by unstimulated osteoblastic cell lineages.
14
 
 PDGF plays an essential role in regulation, migration, proliferation and 
survival of mesenchymal cell lineages. It has mitogenic effects on stem cells 
and osteoblasts, stimulates pre-mitotic partially differentiated osteoprogenitor 
cells, stimulates cell replication of endothelial cells and promotes 
angiogenesis. It modulates the effects of other growth factors and promotes 
perivascular healing of the wound. It also plays a crucial role in mechanisms 
of physiologic cicatrisation.
 17, 51
 
 
b. TGF –β : Of the three isoforms TGF-β1 is the most significant. It is an 
inflammatory regulator and the most powerful fibrosis agent amongst all 
cytokines.
12
 
TGF-β1 and TGF-β2 activate fibroblasts, which undergo cell division 
and produce collagen 
66
; control cellular differentiation and proliferation of 
cementoblasts; activate osteoprogenitor cells and further differentiates them to 
produce bone matrix; activate endothelial cells to produce new capillaries; 
stimulate mesenchymal stem cells to induce mitosis so as to provide the large 
population of wound healing cells needed for completion of healing. 
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c. VEGF : It is the most powerful and omnipresent known vascular growth 
factor. The main role is in initiation of angiogenesis 
d. IGF -1  : Although present mainly in plasma it exerts chemotactic effects 
towards human osteoblasts
64
, regulates cell migration, proliferation , 
differentiation and matrix synthesis. Acts as cell multiplication mediators in 
apoptosis by inducing survival signals protecting cells.  
           
 
 
 
3. Role of leukocytes 
Fibrin mesh provides natural immunity under the influence of 
fibrinogen degradation products (FDP) that stimulate the migration of 
neutrophils, modulates phagocytosis and enzymatic degradation of the 
neutrophils. Also chemotactic agents trapped in fibrin control wound 
colonization by macrophages.
26 
Leukocytes trapped in PRF have anti-infectious effect and act as an 
immune regulation node. PRF contains all key immune cytokines like IL 1β, 
IL 6, IL 4 and TNF. 
26
 They have the ability to control the inflammatory 
response at the wound site.  
Figure 1 : Stages of osteoblast lineage with different growth factors 
(Hughes et al)51 
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Kawamura et al
56
 also demonstrated that PRF may act as supportive 
matrix for BMPs. Thus, indicating role of PRF on wound healing. 
3.3.2 Parts of PRF 
As suggested by Choukroun
19
, centrifugation of patients blood results in into 
three separate layers i.e blood clot at the bottom, fibrin matrix in the middle (PRF) 
and platelet poor plasma on top.  
Histological analyses by Dohan et al
28
 in 2006 determined the platelet 
distribution within the various layers of the centrifuged blood: The platelets 
accumulate in the lower part of the fibrin clot, mainly at the junction between the red 
cells (red thrombus) and the PRF clot itself. This observation highlights the finding 
that the red extremity of PRF would be more effective than the higher part of the 
fibrin clot and would be of maximum clinical application. 
 
3.3.3 Activation 
Activation and degranulation of platelets is important to initiate and support 
their aggregation at the healing site. Given the absence of anticoagulant, activation of 
platelets in contact with silica of glass tube walls starts the coagulation cascade. 
Figure 2 : Parts of Platelet Rich Fibrin
28 
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Fibrinogen forms fibrin in the presence of physiologic thrombin. Post centrifugation 
fibrin is obtained in the middle of the tube with massively concentrated platelets 
Activation of platelets, thus releases the cytokines (IL-1 beta, IL-6, TNF-
alpha) and growth factors (TGF beta 1, PDGF, VEGF, EGF) that stimulates cell 
migration and proliferation within the fibrin matrix and thus begins the first stage of 
healing.
26 
3.3.4 Technical significance 
 According to a study by Su et al
98
 in 2009, platelet rich fibrin allows 
continuous release of growth factors for over 300 minutes following its preparation. 
Hence, it must be used immediately after preparing. The progressive release of 
cytokines and leukocytes continues for a period of 7-11 days, as the fibrin network 
disintegrates.
95
 
Slow and natural polymerization of PRF in the presence of physiologic 
thrombin gives it the crucial three dimensional organization of fibrin network. This 
characteristic fibrin network provides it with great elasticity, thus forming a very 
strong PRF membrane. Waiting for more than a minute or two may cause the fibrin to 
polymerize in a diffuse way, leaving behind only a small poorly formed clot in the test 
tube.
27 
3.3.5 The various advantages of PRF include (Dohan et al)
 26,27,28,30
:   
1. Completely autogenous 
2. Extended growth factor release for 7 days   
3. Simple and faster technique 
4. In-expensive 
5. No requirement of any additive constituent such as bovine thrombin 
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6. No biochemical handling involved 
7. No associated immune reactions  
8. No associated infections 
9. Acts as an ‘immune regulation node’  
10. Has anti- inflammatory effects 
3.3.6 Limitations  
Connell
23
 in 2007 raised concern regarding the safety issue of PRF 
methodology. He commented on the types of tubes to be used to produce PRF and the 
possible hazards of silica containing glass tubes.  
However, Dohan et al
29
 in the same year conducted a cytotoxicity analysis of 
PRF on wide range of human cells and concluded that silica microparticles coating 
these tubes are not cytotoxic for the tested human cells. They also reported improved 
mitotic proliferation and suggested contact with silica is necessary to start the 
polymerisation process as silica behaves as clot activator. Thus, to produce PRF either 
dried glass tubes or glass coated plastic tubes must be used. 
Other sensitive issues not yet revealed, that may influence the nature of PRF 
include variation in quantity and quality of PRF with aging, influence of systemic 
diseases (thrombocytopenia, bleeding disorders, diabetes, leukocyte adhesion 
syndromes etc), nutrition, environmental or racial differences, blood profile, 
autoimmunity and genetic predisposition.  
PRP v/s PRF  
According to Mosesson et al
73
, who described the structural and biological 
features of fibrinogen and fibrin in detail, the 3-dimensional organization of fibrin 
network depends on activation mechanism. 
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1. Strong concentration of thrombin leads to condensed tetramolecular or 
bilateral junctions in turn causing thickening of fibrin polymer. This rigid 
network is not very favourable for cytokine enmeshment and cellular 
migration. However, it can seal biologic tissues well. Such a structural 
organization is observed in platelet rich plasma (PRP). 
 
                      Figure 3 : Structural Organization of PRP and PRF 
2. Weak concentration of thrombin leads to trimolecular or equilateral junctions 
which result in a fibrin matrix that is flexible and can support cytokine and 
cellular migration. Such a flexible elastic and very strong network is seen in 
platelet rich fibrin (PRF).
31
 Unlike PRP, PRF results from a natural and 
progressive polymerization that occurs during the centrifugation process.  
In an in- vitro comparison of PRF with PRP, He et al
48 
 in 2009 
demonstrated gradual extended release of autologous growth factors and better 
induction of osteoblastic differentiation and proliferation by PRF. 
In a clinical trial by Pradeep et al
79
 in 2012 comparative evaluation of 
autologous PRF and PRP in intrabony defects demonstrated equally 
favourable clinical and radiographic results in both groups when compared to 
open flap debridement alone. 
Tetramolecular junctions -PRP Trimolecular junctions -PRF 
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But given the inexpensive nature, less time consuming and less technique 
sensitive and favourable properties of PRF matrix, it is considered as a better choice 
among the two available varieties of platelet concentrates. 
Applications:   
The vast benefits of PRF have led to its applications in different fields of medicine 
and dentistry: 
1. Ear, nose, throat and plastic surgery91 
2. Oral and maxillofacial surgery20,21 
3. Pre-implant and implant surgery 69 
Mazor Z et al
69
 in 2009, used PRF as the sole agent in simultaneous sinus lift and 
implant placement. They demonstrated stabilization of high volume of natural bone in 
the sub-sinus cavity. 
Toffler et al
102
 in 2009 advocated membrane insurance by possibly sealing an 
undetected perforation during lateral window osteotomy procedure using PRF 
membrane 
Simonpieri et al
95
 in 2009
 
reported maxillary reconstruction using FDBA, PRF 
membranes and 0.5% metronidazole solution. Metronidazole solution provided a 
proficient protection of the bone graft against unavoidable bacterial contamination. 
Chang et al
16
 in 2010 reported in their  in-vitro study that platelet rich fibrin can 
modulate the expression of extracellular signal-regulated protein kinase and 
osteprotegrin in human osteoblasts, suggesting potential role in bone regeneration  
Kang et al
55
 in 2011 strongly supported the characteristics of PRF as a 
bioscaffold and reservoir of growth factors for tissue regeneration. 
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Periodontal Applications :  
1. As a resorbable membrane for recession coverage7, 54 
2. As a scaffold for human periosteal tissue and bone tissue engineering40 
3. As a sole grafting material in osseous defects81 
4. As a grafting material in combination with other grafts in osseous 
defects
62,78
 
Kankamendela et al
54 
 in 2009 reported platelet rich fibrin as a potential novel 
root coverage approach for covering localised gingival recession in mandibular 
anterior teeth using combined laterally positioned flap technique and PRF membrane. 
Gassling et al
40
 in 2010 in their in-vitro study compared of PRF with the 
commonly used collagen membrane Bio-Gide
®
 as scaffolds for periosteal tissue 
engineering. The proliferation level as measured by quantitative and qualitative 
revealed higher values for PRF.  Thus, suggesting superior nature of PRF to collagen 
(Bio-Gide
®
) as a scaffold for human periosteal cell proliferation and bone tissue 
engineering. 
Pradeep et al
81
 in 2011 in their clinical trial compared autologous platelet rich 
fibrin to open flap debridement alone in treatment of 3-Wall Intrabony Defects in 
Chronic Periodontitis patients. They observed  mean  reduction in probing depth 
greater in test group (4.55 ± 1.87 mm) than control group (3.21 ± 1.64 mm) while 
mean PAL gain was also found to be greater in test group (3.31 ± 1.76 mm) compared 
to controls (2.77 ± 1.44 mm). Furthermore, significantly greater percentage of mean 
bone fill was found in the test group (48.26 ± 5.72 % ) compared to control (1.80 ± 
1.56 % ). 
Thorat et al
101
 in 2011 performed a controlled clinical trial in order to estimate 
the clinical effects of autologous PRF in treatment of intra-bony defects. All the 
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clinical parameters and radiographic parameters reported greater improvement with 
the use of PRF. Significant reductions in probing depth, CAL gain and greater 
intrabony defect fill was observed. 
4.  COMBINATION APPROACHES 
Choukroun’s PRF has revolutionised the field of regenerative dentistry and motivated 
the researchers and clinicians further to apply this procedure along with tissue 
engineering protocol 
PRF membranes protect the surgical site and promote soft tissue healing and 
PRF fragments when mixed with graft material may function as a “biological 
connector” between the different graft elements, and as a matrix that supports neo-
angiogenesis, capture of stem cells and migration of osteoprogenitor cells to the 
centre of the graft.
102
  
Although the additional benefits of PRF seem to be revolutionizing, only 
limited research is presently available on PRF in combination with bone grafts in 
comparison with bone grafts alone 
 In a 2005 study Sammartino
87
, reported the use of autogenous bone mixed 
with platelet-enriched fibrin glue for simultaneous implant placement in dogs. The 
combination group demonstrated enhanced osseointegration and better bone 
formation than use of autogenous bone alone.  
Choukroun et al
21
 in 2006 attempted to evaluate the potential of PRF in 
combination with freeze-dried bone allograft (FDBA) to enhance bone regeneration in 
sinus floor elevation. After 4 months of healing time, histological maturation of the 
test group appeared to be identical to that of the control group which was for a period 
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of 8 months. Moreover, the quantities of newly formed bone were equivalent between 
the 2 protocols.  
Meyer et al
71
 in 2009
 
advocated that the long-term reliability of β TCP 
associated to growth factors (PRP or PRF) without bone graft, in massive sinus-lift 
procedures induces fewer complications, and the implant success as well as resorption 
rate is comparable to the one obtained by using autologous bone grafts. 
Kanakamadela et al
53
 in 2009 reported combined use of platelet rich fibrin 
and bone graft has for combined periodontic – endodontic furcation defect. They 
reported beneficial results with the combination therapy. 
Simonpieri et al
95
 in 2009 summarised the use of platelet concentrate PRF 
with bone grafting can offer various advantages :  
1. Mechanical protection of grafted materials with PRF membrane.93 
2. PRF fragments act as biological connectors between graft materials.102 
3. Fibrin network facilitates cellular migration, neoangiogenesis, 
vascularisation and survival of graft 
20,28
. 
4. Platelet cytokines are gradually released as fibrin matrix is resorbed69  
5. Self regulation of inflammatory phenomenon within the grafted site 
given the presence of leukocytes and cytokines.
37
 
 
Jang et al
52
 in 2010 determined the ability of silk fibroin powder as 
biomaterial template for the regeneration of peri-implant defects when mixed with 
Choukroun’s PRF in ten New Zealand white rabbits. Histomorphometric analysis 
show greater bone formation and repair of per-implant defects for experimental group 
(silk fibroin and PRF) than in control (unfilled) group. 
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Lekovic  et al
62
 in 2012 compared PRF and bovine porous bone mineral vs 
PRF alone in the treatment of intrabony periodontal defects. The results of this study 
indicated that PRF can improve clinical parameters associated with human intrabony 
periodontal defects. They also observed that the combination of BPBM with PRF had 
the ability to augment the effects of PRF in reducing pocket depth, improving clinical 
attachment levels and promoting defect fill. 
Pradeep et al
78 
 in 2012 combined porous hydroxyapatite graft with platelet 
rich fibrin in management of intabony defects in chronic periodontitis patients. The 
study aimed to explore the additional effectiveness of autologous PRF with bone graft 
material. On evaluation HA addition to PRF increased the regenerative effects than 
observed with PRF alone. 
Thus, given the various advantages of platelet rich fibrin as a replacement 
material and its possible additional benefits in management of periodontal osseous 
defects, the present study was undertaken.  It involved the comparative assessment of 
the efficacy of DMBM (osseograftTM) alone and in combination with platelet rich 
fibrin. 
26 
 
MATERIALS AND METHODS 
The study population was selected from the Outpatient Section of the 
Department of  Periodontics , Tamil Nadu Government Dental College and Hospital, 
Chennai, India. 
 
Inclusion criteria 
• Patients willing for voluntary participation & have signed informed consent. 
• Patients with age group 20-45 years of either gender 
• Systemically healthy subjects 
• Patients with pocket probing depth ≥5mm following phase I therapy  
• Radiographic evidence of vertical bone loss.  
 
Exclusion criteria 
• Patients showing unacceptable oral hygiene maintenance during pre-surgical 
(phase-I) period 
• Patients with history of periodontal therapy - 6 months prior to study 
• Patients under any medication - 6 months prior to study 
• Patients with use of tobacco or tobacco related products  
• Pregnant / Lactating patients 
• Patients with known systemic diseases  
• Patients with any known metabolic disorders   
• Patients with any known allergies 
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STUDY DESIGN  
Ethical clearances were obtained from the institution’s ethical committee and 
the ethical principles were meticulously followed throughout the course of the study.  
Subjects for the study were selected randomly, with no discrimination on the 
basis of sex, caste, religion or socioeconomic status. After explaining the study 
procedure (Annexure 1), written informed consent was obtained from all the subjects 
selected for the study (Annexure 2 & 3). Examination was preceded by a thorough 
medical and dental history of the subjects. Each subject underwent full-mouth 
periodontal probing and charting, and radiographic evaluation (Annexure 4). 
A total of 18 sites in 15 subjects were randomly selected and divided into two groups : 
Group I :    9 sites treated with bone graft (DMBM) alone 
Group II : 9 sites treated with combination of bone graft (DMBM) and     
platelet rich fibrin. 
STUDY PROTOCOL  
1. Institutional ethical committee approval. 
2. Medical history and informed consent. 
3.Complete periodontal examination using a mouth mirror and a Williams periodontal 
probe under artificial light. 
4. Intra-oral evaluation and periodontal examination using clinical parameters namely    
Gingival bleeding index, Plaque index, Pocket probing depth and Clinical attachment 
level 
5. Radiographic evaluation  
6. Phase I therapy and re-evaluation of clinical parameters after 4-6 weeks 
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7. Selection of study sites and random allocation into two groups 
8. Surgical procedures (open flap debridement and graft placement) according to the 
group selection 
9. Post –operative care  
10. Clinical re-evaluation at the end 6 months  
11. Radiographic re-evaluations at the end of 3 and 6 months  
PRE-OPERATIVE  CLINICAL ASSESSMENT 
The clinical parameters evaluated before and after phase I therapy and 6 months post 
surgically included : 
1. Plaque index  
2. Gingival bleeding index  
3. Probing pocket depth in mm (PPD)  
4. Clinical attachment level in mm (CAL)  
Plaque Index  (Silness and Loe 1964) 
93
 
All teeth were examined at 4 sites each (disto-facial, facial, mesio-facial lingual / 
palatal) and were scored as follows : 
Criteria for Scoring: 
Score 0 No plaque 
Score 1 Plaque not visible to the naked eye, detected only by running the 
explorer or by using a disclosing agent 
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Score 2 Thin to moderate accumulation of soft deposits within the gingival 
pocket or on tooth and gingival margin, visible to the naked eye 
Score 3 Abundance of soft matter within gingival pocket and / or on tooth 
surface and margin, inter-dental area stuffed with soft debris 
Calculation :    Plaque index per tooth  = Total score / 4           
               Plaque index per individual      ═  Total P I per tooth   
Total number of teeth examined 
 
Interpretation:   Score   0 –     Excellent oral hygiene 
                              0.1 to 0.9  –  Good oral hygiene 
                              1.0 to 1.9 –   Fair oral hygiene 
                              2.0 to 3.0 -   Poor oral hygiene 
Gingival Bleeding Index (Ainamo & Bay 1975) 
1
 
Starting distobuccally, the probe was inserted slightly into the sulcus and run to the 
buccal and mesial surfaces of every tooth at an angle of about 45
o
. This was repeated 
for all teeth present. Probing was similarly carried out at palatal/lingual sites. Any 
gingival units that exhibited bleeding were recorded. The total number of bleeding 
sites per tooth was thus recorded for every tooth except the third molar. 
Criteria for Scoring 
Positive score (1)  - Presence of bleeding within 10 seconds  
Negative score (0) - Absence of bleeding 
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% of bleeding sites = Total number of positive score       x 100  
        Total number of surfaces of all teeth 
Stent Preparation  
Acrylic occlusal stents were fabricated over the study models. Self cured pink 
acrylic was used for the purpose. The stent covered the occlusal and coronal 1/ 3rd of 
the labial and lingual surfaces of the teeth. It involved one tooth mesially and one 
distally to the study tooth. Vertical grooves were made to guide the placement of the 
probe in the same plane and direction repeatedly during measurements to avoid any 
variation. The  recordings were made using a Williams periodontal probe. 
 
Probing Pocket Depth (PPD)(In mm) 
15
 
Probing Pocket Depth was measured from the gingival margin to the base of 
the pocket in millimeters using Williams Periodontal Probe. The probe was walked 
within the gingival sulcus along the circumference of the tooth. Keeping the probe 
parallel to the long axis of the selected tooth, six measurements were made per tooth 
(Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, Midlingual, and Distolingual). 
Clinical Attachment Level (CAL) 
15
 
Clinical Attachment Level was measured from the Cemento – Enamel Junction 
(CEJ) to the base of the pocket using Williams Periodontal Probe. The probe was 
placed parallel to the long axis of the tooth and readings were recorded at six different 
sites (Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, Midlingual, and 
Distolingual). 
 
PRE-SURGICAL EVALUATION 
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Patients to be included in the study were selected according to the above defined 
criteria. All the selected patients were given oral hygiene instructions and were 
subjected to phase-I periodontal therapy. After 3-4 weeks of phase-I therapy re-
evaluation of the clinical status was performed and patients with acceptable oral 
hygiene (PI ≤ 1) were selected. After correlating with radiographic findings surgical 
procedure was planned. The infrabony defects were randomly assigned to either   
group I or group II. 
SURGICAL PROCEDURE:  
Intra-oral antisepsis and extraoral antisepsis was performed with 0.2% 
chlorhexidine digluconate rinse and 5% povidone iodine solution respectively. The 
operative site was anaesthetized with 2% Lignocaine HCl with adrenaline (1:80,000) 
using block and infiltration techniques. 
 Crevicular incisions were made on the facial and lingual/palatal surfaces, 
extending on tooth on each side of the defect tooth using the Bard Parker blade No.15. 
A full thickness mucoperiosteal flap was reflected using the periosteal elevator. Care 
was taken to preserve maximum amount of interdental papillary tissue. After 
reflection of the flap and exposure of osseous defect, a thorough surgical debridement 
of soft and hard tissue was done using the area specific Gracey curette. No osseous 
recontouring was performed. Debridement was followed by copious 0.9% normal 
saline irrigation. 
       In group I, the defect was filled with DMBM (osseograft
TM
) mixed with saline.                                
In group II, the defect was filled with a combination of PRF and DMBM         
(osseograft
TM
). Freshly prepared PRF gel was obtained after centrifugation and 
immediately used. Following light squeezing between two sterile gauze pieces, it was 
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made into small pieces and mixed with equal proportion of bone graft (1:1 v/v).
62
 The 
mixture was then placed into the osseous defect with light pressure till it filled upto 
the most coronal level of osseous wall. 
The mucoperiosteal flaps were repositioned and secured using 3-0 black silk 
braided sutures. Periodontal dressing (Coe-pacTM) was placed. All patients were 
prescribed systemic antibiotics (amoxicillin 500mg thrice daily, metronidazole, 
400mg twice daily)   and analgesics (paracetamol 500 mg thrice daily ). 
Post operative instructions were given to all the patients. Re-evaluation for any 
acute signs of inflammation or infection was done at 24 hours post surgically. 7 days 
following surgery, the dressing and sutures were removed and surgical site was 
irrigated with normal saline. Patients were observed for any signs or symptoms of 
post operative complications. Patients were reviewed every week for the first four 
weeks. Thereafter depending on patients’ maintenance, recall appointments were 
made after 3 months and finally at 6 months and radiographs were repeated. During 
the entire follow-up period, oral hygiene maintenance was reinforced and 
supragingival scaling was performed, if required. 
PRF preparation 
19, 27
 
               Platelet rich fibrin (PRF) was prepared in accordance with the protocol 
developed by Choukroun et al. Just prior to surgery approximately 5-6ml of 
intravenous blood was drawn from the cubital fossa of the patient. Whole blood was 
collected in a 10-ml sterile glass tube without anticoagulant and immediately 
centrifuged at 3000 rpm for 10 minutes.
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Blood centrifugation resulted in separation of blood into a structured fibrin 
clot in the middle of the tube, just between the red corpuscles at the bottom and 
acellular plasma (Platelet-poor plasma) at the top.
27
 After removal of PPP, PRF was 
easily separated from red corpuscles base [preserving a small red blood cell (RBC) 
layer] using sterile tweezers and scissors. 
RADIOGRAPHIC MEASUREMENTS:  
Intraoral periapical radiographs were taken for each site using long cone 
paralleling technique and XCP holders at baseline, 3 months and 6 months post-
operatively and evaluated. 
The radiographs were digitized using digital camera
82
 (canon powershot sx230 
HS), and images were analysed using corelDRAW software version x6
89
.
 
The following anatomical landmarks (Photograph 10a) of the intrabony defect were 
identified on the radiograph images based on criteria set by Bjorn et al 
9
 and by Schei 
et al 
90 
:  
1. CEJ: The cemento-enamel junction of the tooth with the intrabony defect. 
2. AC: The most coronal position of the alveolar bone crest of the intrabony defect 
when it touches the root surface of the adjacent tooth before treatment, the top of the 
crest.  
3. BD : The most apical extension of the intrabony destruction where the periodontal 
ligament space still retained its normal width before treatment, the bottom of the 
defect.  
If restorations were present, the apical margin of the restoration was used to 
replace the CEJ as a fixed reference point.  
__________________________________________________________Materials and Methods 
34 
 
For measurements, connector line tool of the software was used. A line was 
drawn from CEJ to base of the defect and a perpendicular was then drawn from 
alveolar crest to this line to obtain the distance between CEJ and alveolar crest. Also, 
a line was drawn from CEJ to root apex (Photograph 10b). All measurements were 
recorded in millimetres.  
The following linear measurements were performed 
63,82 
: 
1. CEJ to bottom of the defect (CEJ to BD) = Defect Depth (DD)  
2. CEJ to most coronal extent of the inter-dental alveolar crest (CEJ to AC) 
3. Depth of the intrabony defect at baseline =  (CEJ to BD) - (CEJ to AC)  
4. Correction factor : In order to estimate distortion between the consequent 
radiographs, an anatomically non-variable distance i.e. the root length 
(distance from the CEJ to the root apex (CEJ to RA)) was measured on all the 
radiographs. The correction factor (CF) was calculated as follows: 
                  CEJ to RA (baseline)   = Correction Factor  
                  CEJ to RA (post-op) 
 
In case it was not possible to measure the root length, the crown length was 
assessed (distance from the incisal margin of the crown to the CEJ). 
5. Bone fill (BF) = CEJ to BD (baseline) ---  [ CEJ to BD (post op) x CF ]  
6. Bone fill percentage (BF %) =         Bone fill                      x 100 
                      Defect Depth (at baseline)  
 
7. Bone crest change(BCC) = CEJ to AC (baseline) - [CEJ to AC (post op) x CF] 
8. Bone crest change percentage (BCC % )  =  Bone Crest change   x 100 
                        CEJ – AC (baseline)  
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If the results were negative, this meant that a process of bone resorption had 
occurred.
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9. Amount of original defect resolution (DR) = Bone fill (BF) – bone crest 
change (BCC) 
10. Percentage(%) of original defect resolution =   Defect Resolution      x  100 
             Depth of intrabony defect (Baseline)  
All the above made observations were recorded and subjected to statistical analysis. 
 
ARMAMENTARIUM 
For clinical examination 
 Mouth mirror  
 Williams periodontal probe 
 Curved explorer 
 Dental tweezers 
 Kidney tray 
 Cotton roll 
 Sterilized disposable gloves  
 Disposable facemask 
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For  Phase I Therapy 
 Mouth Mirror 
 Explorer 
 Scalers and Curettes  
 Kidney Tray 
 Cotton Rolls 
 Disposable Gloves, facemask and headcap 
 Disposable syringe 
 Local Anaesthetic solution 
 Aspirating Needle 
For PRF preparation and collection : 
 Sterile cotton and surgical spirit. 
 Disposable syringe 
 Tourniquet  
 Sterile glass test tube 
 Centrifuge 
 Dental tweezers and scissors 
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For surgical procedure : 
 Mouth mirror  
 Williams periodontal probe 
 Dental tweezers 
 Surgical gloves 
 Disposable mouth mask 
 Local anaesthesia 
 Bard parker blade no 15 and handle – straight and contra-angled. 
 Periosteal elevator 
 Area specific Gracey’s curettes and universal curette (Columbia 4R-4L) 
 Straight and  Curved scissors 
 Saline and irrigation syringe 
 Dapen dish 
 DMBM ( osseograft TM) 
 Suture material – 3-0 black silk braided 
 Needle holder 
 Cement spatula and Glass slab 
 Periodontal dressing (Coe pacTM) 
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                                                         Photograph 1 :Surgical Armamentarium 
                    
                
                                            Photograph 2 : Demineralized Bone Matrix (DMBM) 
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                                               Photograph 3 : XCP Holders 
 
 
                         
                                               Photograph 4 : Centrifuge 
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                                               Photograph 5 (a)  : Pre-operative view 
               
                                                               Photograph 5(b) : Intra-operative view 
               
                       Photograph 5(c) : After placement of DMBM 
 
Photograph 5(d) : Post Operative view 
          GROUP I – OPERATIVE VIEWS 
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                              Photograph 6(a) : At Baseline 
                  
                   
Photograph 6(b) : At 3 months 
 
 
                     
         Photograph 6(c) : At 6 months 
 
                   
                      
                                              
GROUP  I – RADIOGRAPHIC VIEWS 
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      ARMAMENTARIUM FOR PRF COLLECTION AND MIXING WITH DMBM 
                                     
                                  Photograph 7(a) : Blood Collection Kit              Photograph 7(b) : Blood immediately before                      
centrifugation 
 
                                                                   
                                                                 Photograph 7(c) Immediately after centrifugation 
                                                
                                    Photograph 7(d) PRF                                                    Photograph 7(e) PRF+DMBM 
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Photograph 8(b) : Intra-operative view 
                                                           
Photograph 8(c) : After placement of PRF+ DMBM 
 
 
 
 
                          
     
                     
               
                          
GROUP II – OPERATIVE VIEWS 
Photograph 8(a) : Pre-operative view 
Photograph 8(d) : Post Operative view 
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                Photograph 9(a) : At Baseline 
 
                            
                                                                                  Photograph 9(b) : At 3 months 
                          
                                                                         Photograph 9(c) : At 6 months 
 
             GROUP II : RADIOGRAPHIC VIEWS 
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Figure 10(a) : Marking the landmarks 
 
 
 
        
                                                                
Figure 10(b) : Measurement of radiographic parameters 
 
 
 
   RADIOGRAPHIC MEASUREMENTS 
CEJ 
Alveolar crest (AC)  
Base of defect (BD) 
Root apex (RA) 
Defect Depth  (DD) 
(RA) 
Intrabony defect 
(IBD) 
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STATISTICAL ANALYSIS 
 
The statistical analysis was done using the computer software program SPSS 
version 16.0 (Statistical Package for Social Science, Version 16). Descriptive data 
are presented as mean ± SD and range values. 
The comparison of mean values was done using Wilcoxon Signed ranks test 
for within a group (intra-group analysis) and Mann-Whitney U test for intergroup 
comparisons to calculate the p-value. For the multivariate analysis Kruskal-Wallis 
test was used to find the significance between the groups. 
In all the above statistical tools the probability value P ≤ 0.5 was considered 
as significant level.   
 
STATISTICAL FORMULA’S USED FOR DATA ANALYSIS. 
 
Wilcoxon Signed Rank Test 
 
The formula is 
 
 
where n is the number of pairs. T is the sum of the ranks for the positive differences. 
We compare Z to the tabulated Normal distribution. 
 
 
Mann-Whitney U-Test 
 
The formula is 
 
where n1 and n2 are the sample sizes in Group I and Group II respectively. T is the 
sum of the ranks for the n1 observations. 
 
____________________________________________________________Statistical Analysis 
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Kruskal-Wallis Test: 
 Kruskal-Wallis one way analysis of variance is applied to populations from 
which the samples drawn  are not normally distributed with equal variances. 
The test statistic is computed from the following formula: 
  
  
      
 
  
 
  
 
   
        
 k= number of groups 
 nj= number of observations in the j
th
 group 
 n= number of observations in all groups combined  
 Rj= sum of ranks in the j
th
 group 
P value 
 The P value or calculated probability was the estimated probability of 
rejecting the null hypothesis (H0) of a study question when that hypothesis was true. 
The smaller the p-value, the more significant the result was said to be. All P-values 
are two tailed, and confidence intervals were calculated at the 95% level. Differences 
between the two populations were considered significant when p ≤ 0.05. 
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RESULTS 
The study compared the use of bone graft (DMBM) alone and in combination 
with platelet rich fibrin (PRF) in treatment of human periodontal intrabony defects. 
A total of 18 sites in 15 patients within the age group of 25-40 years were 
selected for the study. However, 2 sites in each group could not be evaluated after 
surgical management since 2 became medically compromised and 2 were lost during 
follow up period, for reasons unrelated to the study. 
The final results and statistical analysis was done for a total of 14 sites, 7 sites in each 
group.  
       Group I – 7 sites were treated with open flap debridement followed by 
placement of bone graft (DMBM). 
       Group II - 7 sites were treated with open flap debridement followed by 
placement of combination of bone graft (DMBM) and               
platelet rich fibrin (PRF). 
All patients showed good compliance and healing period was uneventful for 
both the groups, without any signs of infections and complications, indicating 
biocompatibility of both grafting modalities. 
The observations and results of various parameters are summarized in the 
tables and figures. Clinical parameters for both the groups are listed in tables 1 and 5 
for their master chart observations and mean ± SD values respectively. Radiographic 
parameters are listed in tables 2, 3, 4 for their master chart observations, correction 
factor values and radiographic parameters respectively.  
 Figures 5,6,7,8 and figures 9, 10,11,12,13 diagrammatically represent clinical 
and radiographic parameters respectively in both the groups. 
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CLINICAL PARAMETERS 
1. Plaque Index (Table 5, Figure 4) 
Intragroup comparison 
Group I : The mean plaque index score at baseline was 0.69±.19 and at 6 months was 
a 0.50± 0.20. The mean reduction in plaque index from baseline to 6 months was 0.19 
which was moderately statistically significant (p=0.059 ). 
Group II : The mean plaque index score at baseline was 0.61± 0.20 and at 6 months 
was a 0.42± 0.24. The mean reduction in plaque index from baseline to 6 months was 
0.18 which was moderately statistically significant (p=0.059 ). 
Intergroup comparison 
Mean difference between group I and group II was 0.08 at baseline and 0.08 at 6 
months which were statistically non-significant (p=0.71, p=0.54 respectively). 
 
2. Gingival Bleeding Index (Table5, Figure 5) 
Intragroup comparison 
Group I : The mean gingival bleeding index score at baseline was 1.00±0.00 and at 6 
months was a 0.29 ± 0.49. The mean reduction in gingival bleeding index from 
baseline to 6 months was 0.71 which was statistically significant (p=0.025 ). 
Group II : The mean gingival bleeding index score at baseline was 1.00±0.00 and at 6 
months was a 0.14± 0.38. The mean reduction in gingival bleeding index from 
baseline to 6 months was 0.86 which was statistically significant (p=0.014 ). 
Intergroup comparison 
Mean difference between group I and group II at 6 months was 0.15 which was 
statistically non-significant ( p=0.71). 
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3. Probing pocket depth (Table 5, Figure 6) 
Intragroup comparison 
Group I : The mean pocket depth at baseline was 7.14 ± 0.69 and at 6 months was a 
3.00  ± 1.53. The mean reduction in pocket depth from baseline to 6 months was 4.14 
which was statistically significant (p=0.017 ). 
Group II : The mean pocket depth at baseline was 7.43 ±1.51 and at 6 months was a 
3.00  ± 1.53. The mean reduction in pocket depth from baseline to 6 months was 4.43 
which was statistically significant (p=0.018 ). 
Intergroup comparison 
The mean difference in pocket depth between group I and group II at baseline was 
0.28 and  at 6 months was 0.29 which were statistically non-significant (p=0.710, 
p=1.00 respectively). 
 
4. Clinical Attachment level (Table 5, Figure 7) 
Intragroup comparison 
Group I : The mean attachment level at baseline was 7.86 ±0.69 and at 6 months was 
a 4.57 ± 1.13. The mean gain in attachment level from baseline to 6 months was 3.29 
which was statistically significant (p=0.017 ). 
Group II : The mean attachment level at baseline was 8.29 ± 1.98 and at 6 months was 
a 3.86 ± 1.46. The mean reduction in attachment level from baseline to 6 months was 
4.43 which was statistically significant (p=0.018 ). 
Intergroup comparison 
Mean difference in attachment level between group I and group II at baseline was 
0.43 and at 6 months was 0.71 which were statistically non-significant (p=0.54, 
p=0.38 respectively). 
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RADIOGRAPHIC PARAMETERS 
1. Defect depth (Table 6, Figure 8) 
Intragroup comparison 
Group I :  
The mean defect depth at baseline was 4.89 ± 1.59 , at 3 months was 3.39 ± 1.23 and 
at 6 months was a 2.79 ± 1.15.  
The mean difference in defect depth from baseline to 3 months was 1.50 which was 
statistically significant (p = 0.18 ) .The mean difference in defect depth from baseline 
to 6 months was 2.10 which was also statistically significant (P=0.18 ).The mean 
difference in defect depth from 3 months to 6 months was 0.60 which was statistically 
non-significant (p=0.176) 
Group II :  
The mean defect depth at baseline was 4.79 ± 3.15 , at 3 months was 2.26 ± 1.23 and 
at 6 months was a 1.31 ± 0.67.  
The mean difference in defect depth from baseline to 3 months was 2.53 which was 
statistically significant (p = 0.18 ) .The mean difference in defect depth from baseline 
to 6 months was 3.48 which was also statistically significant (P=0.18 ). The mean 
difference in defect depth from 3 months to 6 months was 0.95 which was statistically 
non-significant (p=0.128).  
Intergroup comparison 
At 3 months mean difference in defect depth  between group I and group II was 1.13 
which was statistically not significant (p=0.073 ).  
At 6 months mean difference in defect depth  between group I and group II was 1.48 
which was statistically significant (p=0.007 ).  
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2. Bone Fill (Table 6) 
 
Intragroup comparison 
Group I :  
The mean bone fill at 3 months was 1.47 ± 1.26 and at 6 months was a 2.52 ± 1.30. 
The mean difference in bone fill from 3 months to 6 months was 1.05 which was 
statistically significant (p = 0.028 ). 
Group II :  
The mean bone fill at 3 months was 2.73 ± 1.92 and at 6 months was a 4.28 ± 2.64.  
The mean difference in bone fill from 3 months to 6 months was 1.55 which was 
statistically significant (p = 0.028). 
Intergroup comparison 
At 3 months mean difference in bone fill between group I and group II was 1.26 
which was statistically not significant (p=0.383 ).  
At 6 months mean difference in defect depth  between group I and group II was 1.76 
which was statistically not significant (p=0.259 ).  
 
3. Bone Fill % (Table 6, Figure 9) 
 
Intragroup comparison 
Group I :  
The mean bone fill percentage at 3 months was 15.14 ± 11.76 and at 6 months was a 
33.04 ± 21.01. The mean difference in bone fill from 3 months to 6 months was 17.80 
which was statistically significant (p = 0.018). 
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Group II : 
 The mean bone fill at 3 months was 24.86 ± 14.18 and at 6 months was a 39.00 ±  
12.89. The mean difference in bone fill percentage from 3 months to 6 months was 
 14.14 which was statistically significant (p = 0.028). 
Intergroup comparison 
At 3 months mean difference in bone fill percentage between group I and group II 
was 9.72 which was statistically not significant (p=0.318 ).  
At 6 months mean difference in bone fill percentage  between group I and group II 
was 5.96 which was statistically not significant (p=0.259 ).  
 
4. Bone crest change (Table 6) 
Intragroup comparison 
Group I :  
The mean change in bone crest at 3 months was 0.131 ± 0.73 and at 6 months was a 
0.607 ± 0.50. The mean difference in change in bone crest from 3 months to 6 months 
was 0.476 which was statistically not significant (p = 0.128). 
Group II :  
The mean change in bone crest at 3 months was 0.384 ± 0.85 and at 6 months was a 
0.725 ± 1.18. The mean difference in change in bone crest from 3 months to 6 months 
was 0.341 which was statistically not significant (p = 0..499). 
Intergroup comparison 
At 3 months mean difference in bone crest level between group I and group II was 
0.253 which was statistically not significant (p=0.456 ).  
At 6 months mean difference in bone crest level between group I and group II was 
0.118 which was statistically not significant (p=0.620 ).  
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5. Bone Crest change % (Table 6, Figure 10) 
Intragroup comparison 
Group I :  
The mean percentage change in bone crest at 3 months was 2.82 ± 18.22 and at 6 
months was a 14.03 ± 10.58. The mean difference in percentage change in bone crest 
from 3 months to 6 months was 11.21 which was statistically not significant (p = 
0.237). 
Group II :  
The mean percentage change in bone crest at 3 months was 2.90 ± 22.40 and at 6 
months was 8.49 ± 20.03. The mean difference in percentage change in bone crest 
from 3 months to 6 months was 5.59 which was statistically not significant (p = 
0.398). 
Intergroup comparison 
At 3 months mean percentage difference in bone crest level between group I and 
group II was 0.08 which was statistically not significant (p=0.805 ).  
At 6 months mean percentage difference in bone crest level between group I and 
group II was 5.54 which was statistically not significant (p=0.620 ).  
 
6. Defect resolution % (Table 6, Figure 11) 
Group I :  
The mean percentage defect resolution at 3 months was 12.43 ± 14.14 and at 6 
months was a 36.92 ± 29.12. The mean difference in percentage defect resolution 
from 3 months to 6 months was 24.49 which was statistically not significant (p = 
0.063). 
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Group II :  
The mean percentage defect resolution at 3 months was 40.23 ± 29.41 and at 6 
months was 59.52 ± 28.90. The mean difference in percentage defect resolution from 
3 months to 6 months was 19.29 which was statistically not significant (p = 0.176). 
Intergroup comparison 
At 3 months mean percentage defect resolution between group I and group II was 
27.60 which was statistically significant (p=0.038 ).  
At 6 months mean percentage defect resolution between group I and group II was 
22.60 which was statistically not significant (p=0.209 ).  
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Table 1 : Master Chart I – CLINICAL PARAMETERS 
                                                                                                   Group I  
                                                                                                (DMBM) 
S.No Age 
(years) 
Sex  
(M/F) 
PI  
(Baseline) 
GBI  
(Baseline) 
PPD (mm) 
(Baseline) 
 CAL(mm) 
(Baseline) 
 PI  
6 months 
 GBI  
6 months 
 PPD (mm) 
6 months 
 CAL (mm) 
6 months 
1 43 M 1 1 7 8 0.5 0 2 6 
2 28 F 0.5 1 7 7 0.25 0 5 5 
3 29 F 0.75 1 8 8 0.5 0 3 3 
4 44 F 0.75 1 7 7 0.75 1 5 5 
5 35 M 0.50 1 8 8 0.25 0 3 3 
6 26 F 0.75 1 7 9 0.75 1 1 5 
7 24 F 0.5 1 6 8 0.5 0 2 5 
           
Group II  
(PRF-DMBM) 
 Age 
(years) 
Sex  
(M/F) 
PI  
(Baseline) 
GBI  
(Baseline) 
PPD (mm) 
(Baseline) 
 CAL(mm) 
(Baseline) 
 PI  
6 months 
 GBI  
6 months 
 PPD (mm) 
6 months 
 CAL(mm) 
6 months 
1 24 M 0.75 1 8 8 0.75 0 3 3 
2 43 M 0.5 1 7 10 0.25 0 1 5 
3 26 F 0.75 1 5 5 0.25 0 2 2 
4 40 F 0.5 1 10 11 0.25 0 3 5 
5 29 F 0.75 1 7 7 0.75 1 5 5 
6 39 M 0.25 1 8 8 0.25 0 5 5 
7 39 M 0.75 1 7 9 0.5 0 2 2 
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Table 2 : Master Chart II - RADIOGRAPHIC MEASUREMENTS 
Group I (DMBM) 
 Baseline  After 3 months After 6 months  
S.No CEJ-BD CEJ-AC      CEJ-BD     CEJ-AC Correction factor 
CF3 
   CEJ-BD CEJ-AC Correction factor 
CF6 
1 10.95 3.89 7.66 4.41 1.04 6.71 4.40 1.00 
2 8.35 5.84 7.75 5.73 0.99 6.35 4.26 1.07 
3 9.76 4.42 6.68 2.86 1.03 5.57 2.93 1.14 
4 6.81 2.87 5.89 3.34 1.02 6.67 3.64 0.94 
5 10.46 6.87 10.01 6.83 1.03 8.3 7.05 0.97 
6 9.60 3.65 8.88 3.08 1.00 7.79 2.80 1.00 
7 10.20 4.38 8.24 5.37 0.98 7.32 4.47 0.99 
 
Group II (PRF-DMBM) 
 Baseline  After 3 months After 6 months  
S.No CEJ-BD CEJ-AC      CEJ-BD     CEJ-AC Correction factor 
CF3 
   CEJ-BD CEJ-AC Correction factor 
CF6 
1 13.79 4.44 7.05 4.96 1.03 5.53 4.52 1.06 
2 10.63 7.71 8.65 6.96 1.01 7.45 4.80 1.03 
3 5.77 2.14 5.47 2.92 1.03 4.20 2.64 0.97 
4 14.90 5.58 11.11 5.68 1.07 6.73 5.68 1.03 
5 8.13 6.01 6.85 5.86 0.86 6.05 5.17 1.02 
6 8.04 5.54 5.17 3.96 1.00 4.80 4.1 0.99 
7 10.42 6.7 8.26 6.74 0.97 7.60 6.25 0.89 
                   Measurements in millimetres (mm) 
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Table 3 : Correction factor (CF) calculation for radiographic parameters 
Group I (DMBM) 
 CEJ-RA 
( Baseline) 
CEJ-RA 
(3 months) 
CEJ-RA 
(6 months) 
Correction Factor  
(3 months) 
Correction Factor  
(6 months) 
1 18.77 18.10 18.79 1.04 1.00 
2 13.63 13.71 12.71 0.99 1.07 
3 15.19 14.76 13.27 1.03 1.14 
4 11.39 11.16 12.09 1.02 0.94 
5 16.38 15.95 16.96 1.03 0.97 
6 13.60 13.62 13.55 1.00 1.00 
7 13.02 13.24 13.19 0.98 0.99 
   
Group II (PRF-DMBM) 
 CEJ-RA 
( Baseline) 
CEJ-RA 
(3 months) 
CEJ-RA 
(6 months) 
Correction Factor  
(3 months) 
Correction Factor  
(6 months) 
1 15.09 14.61 14.18 1.03 1.06 
2 17.37 17.18 16.86 1.01 1.03 
3 14.69 14.17 15.10 1.03 0.97 
4 21.92 20.40 21.27 1.07 1.03 
5 12.36 14.35 12.10 0.86 1.02 
6 10.46 10.42 10.55 1.00 0.99 
7 17.25 17.79 19.49 0.97 0.89 
Measurements in millimetres (mm) 
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Table 4:  Master Chart III – RADIOGRAPHIC PARAMETERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measurements in millimetres (mm) 
        
 
 Group I (DMBM) 
S.no DD -BL DD  3 DD  6 BF 3 BF  6 BF % 3 BF % 6 BCC 3 BCC 6 BCC % 3 BCC % 6 DR % 3 DR % 6 
1 7.06 3.38 2.31 3.06 4.42 27.9 40.36 -0.7 0.51 -17.99 13.11 33.43 55.38 
2 2.51 1.99 2.21 0.68 1.55 8.1 18.56 0.17 1.28 2.91 21.91 20.31 10.75 
3 5.34 3.93 3.01 2.88 3.41 29.5 77.15 1.47 1.08 33.26 24.43 26.4 43.63 
4 3.94 2.6 2.99 0.8 0.54 11.75 18.82 -0.54 0.55 -18.81 16.08 6.59 0.25 
5 3.59 3.27 1.21 -0.16 2.99 -1.53 28.59 -0.16 0.03 2.32 0.44 0 82.45 
6 5.95 5.8 4.99 0.72 1.81 7.5 18.85 0.57 0.85 15.6 23.29 2.5 16.13 
7 5.82 2.81 2.82 2.32 2.95 22.76 28.96 0.11 -0.05 2.45 -1.03 -2.23 49.82 
 Group II (PRF-DMBM) 
 DD 0 DD 3 DD 6 BF 3 BF 6 BF % 3 BF % 6 BCC 3 BCC 6 BCC % 3 BCC % 6 DR % 3 DR % 6 
1 9.35 2.15 1.07 6.52 7.94 47.28 57.58 0.67 -0.35 15.9 -7.88 62.56 81.18 
2 2.91 1.71 2.73 1.89 2.96 17.78 27.84 0.68 2.77 8.82 35.93 41.58 6.53 
3 3.63 2.62 1.51 0.14 1.7 2.42 29.39 -0.87 -0.42 -40.5 -19.63 -20.11 35.26 
4 9.32 5.81 1.08 3.01 7.97 20.22 53.45 -0.5 -0.27 -8.92 -4.84 26.93 82.62 
5 2.12 0.85 0.9 2.24 1.96 27.55 24.11 0.97 0.73 14.16 12.15 59.9 58.01 
6 2.5 1.21 0.69 2.87 3.29 35.7 40.92 1.58 1.48 28.52 26.71 51.6 72.4 
7 3.72 1.47 1.2 2.41 4.14 23.13 39.73 0.16 1.14 2.34 17.01 59.14 80.65 
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                                       Table 5 : COMPARISON OF CLINICAL PARAMETERS – GROUP I AND GROUP II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                  
Wilcoxon Signed ranks test for Intragroup comarisons                     *Significant 
                Mann-Whitney U test for Intergroup comparisons                                 # Moderately Significant 
  
 
 
 
 
 
Group I Group II Group I  v/s  Group II 
  
  At baseline  At 6 months  At baseline At 6 months  At baseline  
 
 
 
At 6 months  
 
 
 
  
Mean ±SD 
 
Mean ±SD 
p 
value 
 
Mean ±SD 
 
Mean ±SD 
p 
value 
 
Mean diff 
p  
value 
 
Mean diff 
p 
value 
PI  0.69 ± 0.19 0.50 ± 0.20 0.059
#
 0.61 ± 0.20 0.42 ± 0.24 0.059
# 
0.08  0 .71 0.08 0.54 
                    
GBI 1.00 ± 0.00 0.29 ± 0.49 0.025* 1.00 ± 0.00 0.14 ± 0.38 0.014* 0.00  1.00 0.15 0.71 
                    
PPD 
(mm) 
7.14 ± 0.69 3.00 ± 1.53  0.017* 7.43 ± 1.51 3.00 ± 1.53 0.018*      0.29   0.71       0.00 1 
                    
CAL  
(mm) 
7.86 ± 0.69 4.57 ± 1.13 0.017* 8.29 ± 1.98 3.86 ± 1.46 0.018*      0.43   0.54      0.71 0.38 
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Table 6 : COMPARISON OF RADIOGRAPHIC PARAMETERS – GROUP I AND GROUP II 
 Group I Group II Group I v/s Group II 
 At baseline 
 
At 3 
months 
At 6 months  At 
baseline 
At 3 
months 
At 6 months  At 3 months At 6 months 
 Mean±SD Mean±SD Mean±SD p 
value 
Mean±SD Mean±SD Mean±SD p  
value 
Mean 
diff 
p 
value 
Mean 
diff 
p 
value 
Defect depth 
(mm) 
4.89 ± 4.59  3.39 ± 
1.23 
 2.79 ± 1.15 0.035* 4.79 ± 3.15 2.26 ± 
1.23 
1.31 ± 0.67  0.007* 1.13 0.073 1.48 0.007* 
                      
Bone fill 
(mm) 
    -  1.47 ± 
1.26 
 2.52 ± 1.30  0.028*        -  2.73 ± 
1.92 
 4.28 ± 2.64  0.028* 1.26 0.383 1.76 0.259 
                      
Bone fill %     - 15.14 ± 
11.76 
 33.04 ± 21.01 0.018*      - 24.86 ± 
14.18 
39.00 ± 
12.89 
 0.028* 9.72 0.318 5.96 0.259 
                      
Bone crest 
change (mm)  
    -  0.131 ± 
0.73 
0.607 ± 0.50 0.128     - 0.384 ± 
0.85 
0.725 ± 1.18 0.499 0.253 0.456 0.118 0.620 
                      
Bone crest 
change % 
     -  2.82 ± 
18.22 
14.03 ± 10.58 0.237      - 2.90 ± 
22.40 
8.49 ± 20.03 0.398 0.08 0.805 5.54 0.620 
                      
Defect 
Resolution 
% 
     -  12.43 ± 
14.14 
36.92 ± 29.12 0.063     - 40.23 ± 
29.41 
59.52 ± 
28.90 
0.176 27.60 0.038* 22.60 0.209 
                      
                                               
Wilcoxon Signed ranks test for Intragroup comparisons                                   *Significant 
Mann-Whitney U test for Intergroup comparisons                     # Moderately Significant 
Kruskal-Wallis test for the multivariate analysis in individual groups                                               
______________________________________________________________________Results 
 
62 
 
 
 
                  Figure 4 : Comparison of Plaque Index (PI) between group I and group II 
 
   
 
                Figure 5 : Comparison of Gingival Bleeding Index (GBI) between group I and group II 
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               Figure 6 : Comparison of Probing pocket depth (PPD) between group I and group II 
 
 
 
 
               Figure 7 : Comparison of Clinical attachment level (CAL) between group I and group II 
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Figure 8 :  Comparison of Defect Depth (mm) between  group I and group II 
 
 
                 
 
                   Figure 9 : Comparison of percentage of Bone fill between group I and group II 
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    Figure 10 : Comparison of  percentage of Bone crest change between group I and group II 
 
 
 
 
     Figure 11 :  Comparison of percentage of Defect Resolution between group I and group II 
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Figure 12 : Comparison of Radiographic Parameters 
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DISCUSSION 
Periodontal therapy is performed with the primary objectives of gaining access 
to the diseased sites, achieving reduction in pocket depth, arresting further disease 
progression and finally restoring the periodontal tissues lost due to disease process. 
The ultimate aim to achieve periodontal regeneration via new attachment 
formation has been approached by variety by regenerative modalities, but none has 
been established as a gold standard, given their own associated limitations. 
The recent trend of endogenous replacement therapy has shifted the focus to 
application of autologous mitogenic proteins to periodontal wound. One such store 
house of autologous growth factors and leukocytes, recently made available to the 
field of periodontal therapy, is Platelet Rich Fibrin. 
Presently, researchers are in the process of exploring the vast benefits of PRF 
that can revolutionalize the field of periodontal regeneration. However, till date very 
few clinical trials have been attempted on application of PRF alone and in 
combination with bone grafts in management of periodontal intrabony defects. 
Thus, given the limited available literature on PRF in combination with bone 
grafts, this study was planned and undertaken. 
The decision to utilize PRF was made given its advantageous properties, 
inexpensive nature, ease of manipulation and delivery to surgical site. PRF has a 
tendency to get resorbed in approximately 7-10 days.
30
 Hence, DMBM was added 
hypothesizing that it could enhance the effects of PRF by its osteoinductive and 
osteoconductive properties, by maintaining space at the wound site and allowing 
guided tissues regeneration to occur. 
For this purpose, a total of 18 sites in 15 patients were taken up for study, of 
which 4 patients could not be evaluated due to reasons unrelated to the study. Thus a 
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total of 14 sites in 12 patients were evaluated, i.e. 7 sites per group. Patients from age 
group 25-40 years with moderate periodontitis were included in the study. This was in 
accordance with Deas and Mealey’s25 inclusion criteria, that if risk factor especially 
smoking can be eliminated and compliance with maintenance care is high, then 
surgical regenerative therapy can be as beneficial to the patients with aggressive 
periodontitis as to chronic periodontitis. 
Care was taken to include intrabony defects with three or combined wall 
defects only, as they provide the best spatial relationship for defect bridging by 
vascular and cellular elements from PDL and adjacent osseous walls. Also the 
presence of more number of defect walls provide space maintenance, protection and 
retention of grafts.
11
 
On evaluation of clinical parameters, plaque index showed similar clinical 
values in both groups before and after the treatment, with no significant change thus 
suggesting good hygiene maintenance by all patients during the course of the study. 
These results coincide with those of studies by Yukna et al
108
 and Srikanth et al
97
 
who observed that patients undergoing periodontal therapy try to maintain optimal 
oral hygiene. 
According to Rosen et al
85
, periodontal probing and recording of attachment 
levels should not be done for atleast 6 months post-surgically, since probing can 
damage the healing site, thereby diminishing regenerative outcomes. Thus, in the 
present study probing related clinical parameters were recorded at baseline and 6 
months post surgically only. 
The mean pocket depths in both the DMBM and PRF – DMBM groups at 
baseline were 7.14mm and 7.43mm respectively, signifying that cases with similar 
severity of defects were selected for both the groups. Significant reductions were 
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observed in pocket depths of both the groups (4.14 mm in group I and 4.43mm in 
group II) at the end of 6 months. This improvement in combination group was in 
accordance with Lekovic’s observation of 4.47 mm in their PRF-BPBM group62. 
Significant gain in clinical attachment levels were also observed in both the 
groups at the end of 6 months. However, better levels were observed with PRF – 
DMBM combination (4.43 ± 1.81 mm) than with DMBM alone (3.29 ± 1.38 mm). The 
gain was even better than PRF-BPBM group of the comparative study by Lekovic et al 
(3.82 ± 6.78).
62
  
Radiographic assessments were done at baseline, at the end of 3 months and at 
the end of 6 months using consequent intra-oral radiographs. While using radiographs 
in periodontal diagnosis and research technical and geometric variables need to be 
considered. Projection geometry and parameters should be standardized to minimize 
measurement errors in serial radiography (Lang & Hill, 1977)
68
. Pre-fabricated film 
holders like that used in this study may provide projection standardization to a major 
degree. 
As documented by Gupta et al
45
, radiographic evidence of bone changes can 
be observed as early as 3 months post-operatively. Also, it was hypothesized that PRF 
as a rich source of autologous growth factors and cytokines may lead to rapid changes 
in bone formation. Thus, keeping all of this in mind, radiographic evaluations for the 
present study were attempted at an early time period of 3 months.  
On radiographic evaluation, progressively significant reduction in defect depth 
was observed in both the study groups at the end of 3 months and 6 months in 
comparison to baseline. Also, on comparing the two groups with each other 
significantly more reduction in defect depth was observed at the end of 6 months with 
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combination (PRF-DMBM) therapy. Thus, suggesting better regenerative potential of 
addition of PRF to bone graft DMBM. 
 After a follow-up period of  3 months, higher mean bone fill was observed in 
combination group (2.73 ± 1.92 mm) as compared to DMBM group (1.47 ± 1.26 mm) 
Also at 6 months, bone fill was more for PRF-DMBM combination group (4.28 ± 2.64 
mm)  than DMBM group (2.52 ± 1.30 mm). Moreover, the improvement in bone fill in 
combination group was much  more at the end of 6 months which was in accordance 
with Lekovic’s findings in PRF- BPBM group (4.06 ± 0.87 mm)72. 
In the present study, PRF-DMBM group showed mean percentage of bone fill 
to be upto 51.89% at the end of 6 months. However, Pradeep et al
78
 in their recently 
reported clinical trial in intrabony defects observed 69.39±16.52% of bone fill with 
PRF + HA combination at the end of 9 months. The variation in two studies may be 
attributed to the different follow-up periods and dissimilar graft materials used with 
PRF.  
Change in the alveolar crest level is a frequent outcome of surgical periodontal 
therapy. The morphology of osseous defect and the type of therapy performed may 
have an influence on it. In the present study, the mean changes in the level of bone 
crest were statistically not significant. Although minimal in values, amount of change 
in alveolar crest determines the changes in dimensions of original defect. 
Percentage of original defect resolution is an important parameter that takes 
into account not only the amount of bone fill but also the change in alveolar crest 
level, if any. In the present study, a significant change in defect resolution was 
observed as early as 3 months post-operatively. When compared to bone graft 
(DMBM) alone (12.43 %), the combination group showed much higher defect 
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resolution (40.23 %). This was a unique finding not observed in any of the PRF 
related studies, since an early radiographic analysis was not attempted by them.  
Osseous changes as measured by intraoral radiographs may be different from 
the direct observations by surgical re-entry. This may be attributed to our inability to 
accurately determine the radiographic landmarks, obscuration of the deepest portion 
of the defect by facial or lingual cortices or tooth root and overestimation or 
underestimation of radiographic parameters.  
In the present study, an appreciable amount of defect resolution was observed 
at 6 months for PRF-DMBM group (59.52 ± 28.90 %), which was much higher than 
DMBM group (36.92 ± 29.12 %). However, the difference between the two groups 
was statistically non-significant which can be attributed to the possible radiographic 
limitations.  
The present study has shown good results and additional benefits in clinical 
and radiographic parameters when PRF was used in combination with DMBM. Thus in 
future, PRF may prove to be a novel adjunct to conventional regenerative therapeutic 
modalities in management of periodontal osseous defects. 
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SUMMARY AND CONCLUSION 
In the present study, a total of 14 sites with periodontal intrabony defects were 
evaluated for management with demineralised bone matrix (DMBM- osseograftTM) 
alone and in combination with platelet rich fibrin. The aim of the study was to 
evaluate the clinical effectiveness and regenerative potential of both the grafting 
modalities and to explore the additional effectiveness of PRF on DMBM, if any. 
After the collection of clinical and radiographic data over a period of 6 
months, the values were subjected to statistical analysis and the following conclusions 
were drawn : 
1. Both the graft materials, DMBM and PRF were well tolerated by the   
periodontal tissues during the course of the study. 
2. Clinical parameters demonstrated significant improvement in both the groups 
at the end of 6 months. 
3. Radiographic evidence of defect depth reduction and bone fill was observed in 
relation to both groups. The difference at the end of 3 months and 6 months 
was statistically significant. 
4. Addition of PRF revealed its beneficial effect in the combination group with 
evidence of significant defect resolution at an early follow up period of 3 
months. 
Outcomes of periodontal regenerative therapy, that is, its success and failure 
are dependent on multiple factors. Therefore, it is important for us to determine our 
therapeutic goals realistically. Overall parameters such as patient selection, defect 
selection, choice of diagnostic and therapeutic modalities and post operative follow up 
period, all should be taken well into consideration during decision making. 
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Within the limits of present study, addition of Platelet Rich Fibrin to bone 
graft demonstrated successful and promising results. Thus in future, clinical trials 
with larger sample size may be employed to further explore the potential of PRF as a 
grafting modality. 
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Annexure 1: Information Sheet 
 
 
 
 
 
 
INFORMATION SHEET 
 
 We are conducting a study on “ Evaluation of clinical effectiveness of Platelet 
Rich Fibrin and bone graft in management of intrabony defects” among 
patients attending TNGDCH, Chennai and for this study we are selecting 
patients. 
 
 The privacy of patients in research will be maintained throughout the study. 
In event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not 
result in any loss or benefits to which you are otherwise entitled. 
 
 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in management or treatment  
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Annexure 2: Informed Consent Form - English  
 
 
   STUDY TITLE: 
 
“Evaluation of clinical effectiveness of platelet rich fibrin and bone graft in 
management of intrabony defects : A COMPARATIVE STUDY”, 
  
 
Name:        O.P.No: 
 
Address:                  S. No:               Group no: 
 
 
 
            Age / Sex:  
  Tel. no: 
 
 
I, _____________________________________________________ age ________ 
years exercising my free power of choice, hereby give my consent to be included as a 
participant in the study “Evaluation of clinical effectiveness of Platelet Rich Fibrin 
and bone graft in management of intrabony defects: A Comparative study” 
 
I agree to the following: 
  
 I have been informed to my satisfaction about the purpose of the study and 
study procedures including investigations to monitor and safeguard my body 
function. 
 I understand that the lab investigations will require the procurement of my 
blood in required amount. 
 I agree to undergo the surgical procedure involved in the study process. 
 I agree to cooperate fully and to inform my doctor immediately if I suffer any 
unusual symptom. 
 I have informed the doctor about all medications I have taken in the recent 
past and those I am currently taking. 
 I hereby give permission to use my medical records for research purpose. I 
am told that the investigating doctor and institution will keep my identity 
confidential. 
 I am willing for the bone graft placement, knowing the same has been 
procured from healthy donors.  
 
 
Name of the patient   Signature / Thumb impression  
 
 
 
Name of the investigator   Signature   Date 
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Annexure 3: Tamil Consent Form 
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Annexure 4: Proforma 
DEPARTMENT OF PERIODONTICS 
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL 
CHENNAI – 600003 
-----------------------------------------------------------------------------------------------------------------
-------------- 
 
“Evaluation of clinical effectiveness of Platelet Rich Fibrin and bone graft in 
management of intrabony defects: A COMPARATIVE STUDY”, 
 
PROFORMA 
 
 
Date:     O.P. No:                Group no: 
 
Name:     Age / Sex:   Case no : 
 
Address:             Tel. no    Mobile no: 
 
 
Occupation:   Income: 
 
 
Chief Complaint  : 
 
 
 
 
History of presenting illness : 
 
 
 
 
Past Medical History: 
 
 
 
 
Past Dental History: 
 
 
       
 
 
Clinical Examination:    
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PERIODONTAL  EXAMINATION   
 
 
1. PLAQUE INDEX – SILNESS AND LOE (1964) 
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
 
 
Calculation:  
 
Score:          Inference: 
                                                                                    
2. GINGIVAL BLEEDING INDEX – AINAMO AND BAY (1975) 
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
 
Calculation  
 
Score:         Inference: 
 
3. PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) (mm) 
 
 
MAXILLARY:   Buccal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Palatal 
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MANDIBULAR:   Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Labial 
 
 
 
4. INVESTIGATIONS: 
  
        Blood investigations : 
 
 
 
 
 
 
 
 
Radiographic evaluation -  
 
 
 
 
 
 
 
  
 Others : 
 
 
 
 
5. Diagnosis: 
  
 
 
 
 
6. Prognosis: 
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TREATMENT 
 
1.  EMERGENCY / PRELIMNARY PHASE 
 
 
 
 
2. PHASE I 
 
 
 
 
 
3. RE-EVALUATION  (at 4-6 weeks after phase I) 
 
P LAQUE INDEX – SILNESS AND LOE (1964) 
 
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
 
Calculation:  
 
 Score:                                                                                                                             Inference:                                                                                   
 
GINGIVAL BLEEDING INDEX – AINAMO AND BAY (1975) 
 
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score: 
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Inference: 
PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) (mm) 
 
 
MAXILLARY:   Buccal 
CAL                 
PPD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PPD                 
CAL                 
     Palatal 
 
 
MANDIBULAR:   Lingual 
CAL                 
PPD                 
 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
PPD                 
CAL                 
     Labial 
 
 
4. CLINICAL SITE SELECTED FOR STUDY -  
 
 
 
5. PHASE II ( Surgical) : 
 
 
 
 
 
 
6. PHASE III 
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7. PHASE IV 
RE-EVALUATION  &   SUMMARY  
 
 
 
CLINICAL EVALUATION  : 
 
 
 
 
RADIOGRAPHIC EVALUATION  : 
 
 
 
SL 
No 
Indices Baseline Post -op 
3months 6 months 
 
1
. 
 
Plaque index (Silness and Loe, 1964) 
 
   
2
. 
Gingival bleeding index– (Ainamo and 
bay, 1975) 
 
   
Sl. 
No. 
 
Calculations 
 
Baseline 
Post-op 
3 months  6months 
1. Pocket Probing depth ( mm)    
2. Gingival recession  ( mm)    
3. Clinical Attachment level (mm)    
Sl. No. Calculations Baseline Post op 
3months 6months 
1 CEJ to the base of the defect (mm)    
2 CEJ to the alveolar crest of the 
defect (mm) 
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INFERENCE  / RESULT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Signature of the P.G. Student     Signature of the Guide 
 
 
 
    Date:     
 
